{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"ddx41-related-hematologic-malignancy-predisposition","columns":[{"gene":"","key":"population-c1034763d6bf5753d140","label":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","mondoId":"MONDO:0014809","onsetQualifier":null,"originColumnKey":"MONDO:0014809/OMIM:616871","originalViews":[{"key":"MONDO:0014809/OMIM:616871","label":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","scopeLabel":"OMIM:616871","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["055dbde9f284ebb6ea9c0a77c072dac1146108fa5c382a3d135403adc451f832","1296ba56f30c67ca4d7eb786de359219c547c26500892dc8ed5b9de00e280a33","26733c717dae4ea345f76bd880d4d5c3ca0fe65ea25906bb924ad4185ffef64d","44d48b04771c9648a871da0f062eae8bd7c3995747dd333023b92cf61cb2c2b0","45f6f9669401fb877ddb5501b4f813772fe005d9cbdfb77ff1f68b96090c373f","5b55589447db9fc81083a3e1caac0b34c74b3e5308c8097253f2747f62586a89","6813a5dead2c23a58d11064cfd5f2a928cd193aaa8a196e0baf0a8b6d531a3ba","8236cfb7d316debb120124a89b65c9e423033bb5f93d1e0ef8a0e589cd5efa2f","ab6219e6be8c74ad8eeea9b58dd43387aec0a86fd5862b591d95cb58f65286d1","d6d9cae08fc2e1133145e119d25cfa4a0098ec45df710a65aaa005c3e54fe27b","daf5fac6a075a8daa5ad5c1ac2cbd72e9ffd8201092e56eba0b10f2939efec56"],"recordQualifiers":{},"scopeLabel":"OMIM:616871","sourceIds":["OMIM:616871"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-c1034763d6bf5753d140"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0004808","HP:0002099","HP:0005528","HP:0001882","HP:0000964","HP:0031688","HP:0012311"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":11,"sourceGroups":{"omim":5,"published":6}},"features":[{"hpoId":"HP:0004808","label":"Acute myeloid leukemia","primary":true},{"hpoId":"HP:0002099","label":"Asthma","primary":true},{"hpoId":"HP:0005528","label":"Bone marrow hypocellularity","primary":true},{"hpoId":"HP:0001882","label":"Decreased total leukocyte count","primary":true},{"hpoId":"HP:0000964","label":"Eczematoid dermatitis","primary":true},{"hpoId":"HP:0031688","label":"Erythroid dysplasia","primary":true},{"hpoId":"HP:0012311","label":"Increased total monocyte count","primary":true},{"hpoId":"HP:0002665","label":"Lymphoma","primary":false},{"hpoId":"HP:0002863","label":"Myelodysplasia","primary":false},{"hpoId":"HP:0005505","label":"Refractory anemia","primary":false},{"hpoId":"HP:0002725","label":"Systemic lupus erythematosus","primary":false}],"ledeHtml":"DDX41-related hematologic malignancy predisposition syndrome is a rare inherited condition. It makes people more likely to develop certain types of blood cancers when they are adults. These cancers mainly affect a specific type of blood cell called myeloid cells. The cancers that develop include myelodysplastic syndrome and acute myeloid leukemia. Sometimes people with this syndrome may also develop other immune-related problems. These include sarcoidosis, lupus, asthma, eczema, or juvenile arthritis. They may develop these conditions before or in the absence of developing blood cancer.","mondoId":"MONDO:0014809","node":{"canonicalSlug":"ddx41-related-hematologic-malignancy-predisposition","comparisons":[{"documentSha256":"85cf5f0a6897561d14c2e78a685297af3035c38e516ed510c7f2f809b57f0104","key":"legacy-ddx41-related-hematologic-malignancy-predisposition","kind":"legacy","label":"DDX41-related hematologic malignancy predisposition syndrome","memberIds":["MONDO:0014809"],"mondoId":"MONDO:0014809","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/ddx41-related-hematologic-malignancy-predisposition.85cf5f0a6897561d14c2e78a685297af3035c38e516ed510c7f2f809b57f0104.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"DDX41-related hematologic malignancy predisposition syndrome","originalSourceId":"ORPHA:488647","paragraphs":["DDX41-related hematologic malignancy predisposition syndrome is a rare inherited condition. It makes people more likely to develop certain types of blood cancers when they are adults. These cancers mainly affect a specific type of blood cell called myeloid cells. The cancers that develop include myelodysplastic syndrome and acute myeloid leukemia. Sometimes people with this syndrome may also develop other immune-related problems. These include sarcoidosis, lupus, asthma, eczema, or juvenile arthritis. They may develop these conditions before or in the absence of developing blood cancer."],"rawAttribution":"MONDO:0014809","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:03:03Z","upstream":"PlainLanguagePilotV2-Jan24","url":"https://rarediseases.info.nih.gov/diseases/17899"},"ownColumnKeys":["population-c1034763d6bf5753d140"],"publication":"published","relationships":[{"kind":"parent","label":"hereditary neoplastic syndrome","mondoId":"MONDO:0015356","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"reported","key":"055dbde9f284ebb6ea9c0a77c072dac1146108fa5c382a3d135403adc451f832","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0031688","is_excluded":false,"label":"Erythroid dysplasia","onset_id":null,"reference":"OMIM:616871","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"1296ba56f30c67ca4d7eb786de359219c547c26500892dc8ed5b9de00e280a33","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0005528","is_excluded":false,"label":"Bone marrow hypocellularity","onset_id":null,"reference":"PMID:26712909","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"26733c717dae4ea345f76bd880d4d5c3ca0fe65ea25906bb924ad4185ffef64d","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0002665","is_excluded":false,"label":"Lymphoma","onset_id":null,"reference":"OMIM:616871","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"44d48b04771c9648a871da0f062eae8bd7c3995747dd333023b92cf61cb2c2b0","raw":{"aspect":"P","body_system":"respiratory","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0002099","is_excluded":false,"label":"Asthma","onset_id":null,"reference":"OMIM:616871","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"45f6f9669401fb877ddb5501b4f813772fe005d9cbdfb77ff1f68b96090c373f","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0002725","is_excluded":false,"label":"Systemic lupus erythematosus","onset_id":null,"reference":"OMIM:616871","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"5b55589447db9fc81083a3e1caac0b34c74b3e5308c8097253f2747f62586a89","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0002863","is_excluded":false,"label":"Myelodysplasia","onset_id":null,"reference":"PMID:25920683","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"6813a5dead2c23a58d11064cfd5f2a928cd193aaa8a196e0baf0a8b6d531a3ba","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0005505","is_excluded":false,"label":"Refractory anemia","onset_id":null,"reference":"PMID:25920683","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"8236cfb7d316debb120124a89b65c9e423033bb5f93d1e0ef8a0e589cd5efa2f","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0012311","is_excluded":false,"label":"Increased total monocyte count","onset_id":null,"reference":"PMID:25920683","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"ab6219e6be8c74ad8eeea9b58dd43387aec0a86fd5862b591d95cb58f65286d1","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001882","is_excluded":false,"label":"Decreased total leukocyte count","onset_id":null,"reference":"PMID:26712909","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"d6d9cae08fc2e1133145e119d25cfa4a0098ec45df710a65aaa005c3e54fe27b","raw":{"aspect":"P","body_system":"skin","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000964","is_excluded":false,"label":"Eczematoid dermatitis","onset_id":null,"reference":"OMIM:616871","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"daf5fac6a075a8daa5ad5c1ac2cbd72e9ffd8201092e56eba0b10f2939efec56","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:616871","disease_name":"Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0004808","is_excluded":false,"label":"Acute myeloid leukemia","onset_id":null,"reference":"PMID:25920683","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17899\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0014809\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>PlainLanguagePilotV2-Jan24</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>DDX41-related hematologic malignancy predisposition syndrome is a rare inherited condition. It makes people more likely to develop certain types of blood cancers when they are adults. These cancers mainly affect a specific type of blood cell called myeloid cells. The cancers that develop include myelodysplastic syndrome and acute myeloid leukemia. Sometimes people with this syndrome may also develop other immune-related problems. These include sarcoidosis, lupus, asthma, eczema, or juvenile arthritis. They may develop these conditions before or in the absence of developing blood cancer.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17899\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"ddx41-related-hematologic-malignancy-predisposition","sourceDocuments":[{"name":"GARD: DDX41-related hematologic malignancy predisposition syndrome","reviewed":null,"source_release":"2026-10-21T17:03:03Z","url":"https://rarediseases.info.nih.gov/diseases/17899"},{"name":"MONDO: DDX41-related hematologic malignancy predisposition syndrome","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0014809"}],"sourceNote":"","synonyms":["DDX41 hereditary neoplastic syndrome","DDX41-related hematologic malignancy predisposition syndrome","hereditary neoplastic syndrome caused by mutation in DDX41","MPLPF","myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to"],"takeawayHtml":"","title":"DDX41-related hematologic malignancy predisposition syndrome"},"schemaVersion":1}
